Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Natera Inc (NQ: NTRA )

127.87 +2.12 (+1.69%)
Streaming Delayed Price Updated: 10:49 AM EDT, Oct 11, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Natera Inc

< Previous 1 2 3 4 5 6 Next >
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Innate Pharma (NASDAQ:IPHA) stock increased by 13.7% to $3.32 during Thursday's pre-market session. The market value of their outstanding shares is at $264.6... 
Via Benzinga
87 Biggest Movers From Yesterday
Gainers Sunshine Biopharma, Inc. (NASDAQ: SBFM) shares jumped 150% to close at $3.80 on Wednesday. Sunshine Biopharma, last month, priced its 1.88 million unit uplisting to... 
Via Benzinga
Check Out What Whales Are Doing With NTRA
A whale with a lot of money to spend has taken a noticeably bearish stance on Natera. Looking at options history for Natera (NASDAQ:NTRA) we detected 39 strange trades. 
Via Benzinga
So What's Happening With Natera Shares?
Natera Inc (NASDAQ:NTRA) shares are trading lower by 31.2%... 
Via Benzinga
Mid-Afternoon Market Update: Crude Oil Dips 12%; Cricut Shares Plunge
U.S. stocks traded higher toward the end of trading, with the Nasdaq surging 400 points on Wednesday. The Dow traded up 2.09% to 33,314.85 while the NASDAQ rose 3.45% to 13,236.86... 
Via Benzinga
3 Reasons Why This Natera Analyst Says The Selloff Is Overdone
Natera Inc (NASDAQ: NTRA) analyst Kyle Mikson of Canaccord Genuity Capital reiterated a Buy rating Wednesday on the genetic testing company... 
Via Benzinga
USO, XOM, MRO, DVN: Why Are Oil Stocks Down Today?
Oil stocks are on their way down today and we're diving into what has these shares slipping in a market update for Wednesday! 
Via InvestorPlace
Why Is Natera (NTRA) Stock Down Today?
NTRA stock has lost more than 35% following a short report by Hindenburg Research. The report alleges fraud, among other claims. 
Via InvestorPlace
Mid-Day Market Update: Nasdaq Surges 375 Points; Bumble Shares Spike Higher
U.S. stocks traded higher midway through trading, with the Nasdaq surging 375 points on Wednesday. The Dow traded up 2% to 33,284.15 while the NASDAQ rose 2.93% to 13,170.68. The... 
Via Benzinga
Analyst Ratings For Natera
Over the past 3 months, 4 analysts have published their opinion on Natera (NASDAQ:NTRA) stock. These analysts are typically employed by large Wall Street banks and tasked with... 
Via Benzinga
Natera: Q4 Earnings Insights
Natera (NASDAQ:NTRA) reported its Q4 earnings results on Thursday, February 24, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Natera... 
Via Benzinga
50 Stocks Moving In Wednesday's Mid-Day Session
Gainers Sunshine Biopharma, Inc. (NASDAQ: SBFM) rose 148% to $3.78. Sunshine Biopharma, last month, priced its 1.88 million unit uplisting to Nasdaq at $4.25 per unit. Direct... 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
During Wednesday's session, 35 companies made new 52-week lows. 52-Week High And Low Highlights: The company with the largest market cap to set a new 52-week low was... 
Via Benzinga
Natera's Debt Overview
Over the past three months, shares of Natera (NASDAQ:NTRA) decreased by 34.50%. Before we understand the importance of debt, let us look at how much debt Natera has. Check... 
Via Benzinga
Mid-Morning Market Update: Markets Open Higher; Dow Jumps Over 600 Points
U.S. stocks traded opened on a strong note this morning, with the Dow Jones jumping more than 600 points on Wednesday. Following the market opening Wednesday, the Dow traded up 1.... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 8, 2022
Upgrades According to Janney Montgomery Scott, the prior rating for Wintrust Financial Corp (NASDAQ:WTFC) was changed from Neutral to Buy. Wintrust Finl earned $1.58 in the fourth... 
Via Benzinga
The Daily Biotech Pulse: Orphazyme Plunges On Regulatory Setback In Europe, Pulmonx Earnings Disappoint, Amicus Declines To Spin Off Genetic Medicine Company
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Appoints COO David Hering As Interim CEO Adagio Therapeutics, Inc., (... 
Via Benzinga
FeganScott Announces Investigation into Prenatal Testing Options Revealing Flawed Genetic Results
--News Direct-- 
Via News Direct
7 Stocks to Buy in November in Light of Their October Dip
October was a good month in the markets. It won't be easy to find stocks to buy on the dip. However, here are seven that will do the trick. 
Via InvestorPlace
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front... 
Via Benzinga
Medicare Coverage For Natera's Signatera For Pan-Cancer Immunotherapy Monitoring
CMS Molecular Diagnostics Services Program (MolDX) has issued a final local coverage determination (LCD) for pan-cancer immunotherapy monitoring using Natera Inc... 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
Before 10 am on Friday, 110 companies set new 52-week lows. Interesting Points From Today's 52-Week Lows: Humana (NYSE:HUM) was the biggest company on a market cap... 
Via Benzinga
Natera Raises FY21 Sales Outlook After Mixed Q3 earnings
Natera Inc (NASDAQ: NTRA) posted Q3 sales of $158.1 million, +61% Y/Y, beating the consensus of $151.36 million, driven by an increase in test volume and product... 
Via Benzinga
Natera Inc (NTRA) Q3 2021 Earnings Call Transcript
NTRA earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck's Oral Antiviral COVID-19 Pill Authorized In UK Merck &... 
Via Benzinga
Exposures COVID-19
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc... 
Via Benzinga
CEO And President Of Natera Trades $2.4M In Company Stock
Leonard Steven Chapman, CEO And President at Natera (NASDAQ:NTRA), made a large buy and sell of company shares on October 5, according to a new SEC filing. What Happened: A Form 4... 
Via Benzinga
Topics Regulatory Compliance
Exposures Legal Regulatory
Notable Natera Insider Trades $3M In Company Stock
Burkes Michael Brophy, Chief Financial Officer at Natera (NASDAQ:NTRA), made a large buy and sell of company shares on September 28, according to a new SEC filing. What Happened:... 
Via Benzinga
Topics Regulatory Compliance
Exposures Legal Regulatory
CEO And President Of Natera Trades $3.41 Million In Company Stock
Leonard Steven Chapman, CEO And President at Natera (NASDAQ:NTRA), made a large buy and sell of company shares on September 24, according to a new SEC filing. What Happened: A... 
Via Benzinga
Topics Regulatory Compliance
Exposures Legal Regulatory
Return on Capital Employed Overview: Natera
After pulling data from Benzinga Pro it seems like during Q2, Natera (NASDAQ:NTRA) brought in sales totaling $142.03 million. However, earnings decreased 82.96%, resulting in a... 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.